New Implications of Anti-oxidative Stress Therapy for Atherosclerotic Cardiovascular Diseases

doi:10.3969/j.issn.1673-5765.2017.01.017

Abstract

Abstract:

Many studies have shown that oxidative stress, immunology and inflammation are associated with each other, playing an important role in arteriosclerosis. As an emerging therapy, anti-oxidative stress therapy can further improve the treatment of atherosclerosis. Antioxidants can be divided into natural antioxidants and synthetic antioxidants. Probucol is a synthetic antioxidant, which has a strong antioxidant capacity and plays an important role in reducing vascular restenosis and cardiovascular and cerebrovascular events.

Key words: Oxidative stress; Antioxidant; Atherosclerosis; Inflammation

摘要：

许多研究已经表明，氧化应激、免疫和炎症都是相互联系的，对动脉粥样硬化的发生发展起着重要的作用。抗氧化应激治疗作为一种新兴的治疗，可进一步完善动脉粥样硬化的治疗方案。抗氧化剂可分为天然抗氧化剂和合成抗氧化药物，普罗布考是一种合成的抗氧化药物，具有较强的抗氧化能力，在降低血管再狭窄和心脑血管事件中有着重要的作用。

关键词: 氧化应激; 抗氧化剂; 动脉粥样硬化; 炎症

ZENG Yan. New Implications of Anti-oxidative Stress Therapy for Atherosclerotic Cardiovascular Diseases[J]. Chinese Journal of Stroke, 2017, 12(01): 85-88.

曾彦. 动脉粥样硬化性心血管疾病抗氧化应激治疗的新启示[J]. 中国卒中杂志, 2017, 12(01): 85-88.

References

1 Saini HK，Xu YJ，Amarjit S，et al. Pharmacological

basis of different targets for the t reatment of

atherosclerosis[J]. J Cell Mol Med，2005，9：818-839.

2 Libby P. Counterregulation rules in atherothrombosis[

J]. J Am Coll Cardiol，2012，59：1438-1340.

3 Szmitko PE，Wang CH，Weisel RD，et al. Biomarkers

of vascular disease l inking inf lammat ion to

endothelial activation：Part II[J]. Circulation，2003，

108：2041-2048.

4 Kim H，Yun J，Kwon SM，et al. Therapeut ic

strategies for oxidative stress-related cardiovascular

diseases：Removal of excess reactive oxygen species

in adult stem cells[J]. Oxid Med Cell Longev，2016，

2016：2 483 163.

5 Kurien BT，Hensley K，Bachmann M，et al. Oxidatively

modif ied autoant igens in autoimmune

diseases[J]. Free Radic Biol Med，2006，41：549-556.

6 王倩，汪海. 具有抗动脉粥样硬化作用的天然药物及

其单体化合物[J]. 世界科学技术，2002，5：52-58.

7 李小刚. 抗氧化剂的临床应用现状[J]. 中国卒中杂志，

2010，5：143-149.

8 Jialal I，Devaraj S. Vitamin E supplementation and

cardiovascular events in high-risk patients[J]. N Engl

J Med，2000，342：1917-1918.

9 Collaborative Group of the Primary Prevention

Project. Low-dose aspirin and vitamin E in people

at cardiovascular risk：a randomised trial in general

practice[J]. Lancet，2001，357：89-95.

10 Stephens NG，Parsons A，Schof ield PM，et al.

Randomised controlled trial of vitamin E in patients

with coronary disease：Cambridge Heart Antioxidant

Study (CHAOS)[J]. Lancet，1996，347：781-786.

11 Noguchi N，Gotoh N，Niki E. Effects of ebselen

and probucol on oxidative modifications of lipid and

protein of low density lipoprotein induced by free radicals[J]. Biochim Biophys Acta，1994，1213：176-

182.

12 Davignon J. Atorvastatin：a statin with a large

spectrum of action[J]. Atherosclerosis ID research

alert，1997，2：233-252.

13 王东，丁华，徐红岩，等. 洛伐他汀、普罗布考对小鼠巨

噬细胞源性泡沫细胞内胆固醇含量的影响[J]. 中国药

理学通报，2004，20：680-684.

14 秦玲，赵学忠，张国志，等. 急性冠脉综合征患者细胞

黏附分子和C反应蛋白的变化[J]. 吉林大学学报医学

版，2005，3l：799-801.

15 Kuzuya M，Kuzuya F. Probucol as an antioxidant and

antiatherogenic drug[J]. Free Radic Biol Med，1993，

14：67-7.

16 赵晓晖，周媛，陈翠荣，等. 普罗布考联合阿托伐他汀

对脑梗死颈动脉粥样硬化斑块稳定性的影响[J]. 中国

动脉硬化杂志，2010，18：380-384.

17 王劲松，余金明. 普罗布考抗氧化和预防再狭窄作用

的Meta分析[J]. 中国动脉硬化杂志，2008，16：781-

786.

18 杨宝峰. 药理学[M]. 7版. 北京：人民卫生出版社，

2008：270-271.

19 Yokoi H，Daida H，Kuwabara Y，et al. Effectiveness

of an antioxidant in preventing restenosis after

percutaneous transluminal coronary angioplasty：the

probucol angioplasty restenosis trial[J]. JACC，1997，

30：855-862.

20 Rodés J，Côté G，Lespérance J，et al. Prevention of

restenosis after angioplasty in small coronary arteries

with probucol[J]. Circulation，1998，97：429-436.

21 Tardif JC，Grégoire J，Schwartz L，et al. Effects of

AGI-1067 and probucol after percutaneous coronary

interventions[J]. Circulation，2003，107：552-558.

22 Wakeyama T，Ogawa H，Iida H，et al. Effects of

candesartan and probucol on restenosis after coronary

stenting results of insight of stent intimal hyperplasia

inhibition by new angiotensin II receptor antagonist

(ISHIN) trial[J]. Circ J，2003，67：519-524.

23 Sawayama Y，Shimizu C，Maeda N，et al. Effects

of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic

hypercholesterolemia Fukuoka Atherosclerosis

Trial (FAST)[J]. J Am Coll Cardiol，2002，39：610-

616.

24 Miettinen Tatu A，Huttunen JK，Naukkarinen V，et

al. Long-term use of probucol in the multifactorial

primary prevention of vascular disease[J]. Am J

Cardiol，1986，57：49H-54H.

25 王劲松，余金明. 普罗布考可改善血管病高风险人群

冠状动脉事件结局[J]. 中国动脉硬化杂志，2008，16：

763-766.

26 邹春颖，于凤伟，高凤荣. PAS方案治疗动脉粥样硬化

血栓形成型脑梗死的疗效[J]. 中国老年学杂志，2011，

12：2205-2206.

27 李晓军，肖卫军. 普罗布考对颈动脉粥样硬化不稳定

斑块影响[J]. 中国卒中杂志，2010，5：130-133.

28 Yamashita S，Hbujo H，Arai H，et al. Long-term

probucol treatment prevents secondary cardiovascular

events：a cohort study of patients with heterozygous

fami l ial hypercholesterolemia i n Japan[J ]. J

Atheroscler thromb，2008，15：292-303.

29 Kasai T，Miyauchi K，Kubota N，et al. Probucol

therapy improves long-term (>10-year) survival after

complete revascularization：a propensity analysis[J].

Atherosclerosis，2012，220：463-469.

30 王龙，胡晓，李枚，等. 脑卒中高危人群氧化应激指标

测定及颈动脉粥样硬化危险因素分析[J]. 中华老年心

血管病杂志，2015，9：1125-1128.

31 Tr pkovic A，Resanovic I，Stanimirovic J，et al.

Oxidized low-density lipoprotein as a biomarker of

cardiovascular diseases[J]. Crit Rev Clin Lab Sci，

2015，52：70-85.

32 Liu J，Li MH，Lu H，et al. Effects of probucol on

restenosis after percutaneous coronary intervention：

a systematic review and meta-analysis[J]. PLoS One，

2015，10：e0 124 021.

33 Di Piet ro N，Formoso G，Pandol f i A，et a l，

Physiology and pathophysiology of oxLDL uptake

by vascular wall cells in atherosclerosis[J]. Vascul

Pharmacol，2016，84：1-7.

[1]	LI Yuerong, QIN Xiude, DANG Zhaohui, LU Yunwei, CAI Tiantian, CAI Haobin, BU Fan. Research Progress of Microglia on Mediating Central Post-Stroke Pain [J]. Chinese Journal of Stroke, 2024, 19(8): 967-972.
[2]	WANG Minjie, HAN Cong, DUAN Lian. Moyamoya Angiopathy and Immune-Related Diseases [J]. Chinese Journal of Stroke, 2024, 19(7): 747-754.
[3]	LI Yanjiang, LIU Tonghui, TIAN Hui, SUN Yan, ZHANG Yong. Comparative Study on the Safety and Prognosis of Drug-Coated Balloon Angioplasty and Conventional Balloon Angioplasty in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis [J]. Chinese Journal of Stroke, 2024, 19(7): 803-808.
[4]	ZHAO Chenyang, LI Jin, LI Dongye, QIAO Huiyu, ZHAO Xihai, ZHOU Dan. Study on the Predictive Value of the Intracranial and Carotid Arteries Coexisting Atherosclerotic Plaque Distribution Characteristics for the Risk of Ischemic Stroke Recurrence [J]. Chinese Journal of Stroke, 2024, 19(6): 647-654.
[5]	LIANG Xiaoxue, GUO Li. Obesity-Related Chronic Inflammation and Cerebro-Metabolic Disease [J]. Chinese Journal of Stroke, 2024, 19(2): 138-144.
[6]	WANG Yanling, WANG Xuemei. A Case Report on the Treatment of Multiple Cerebral Vascular Stenosis with Aortic Arch Ulcer Plaque Using Probucol Combined with Atorvastatin [J]. Chinese Journal of Stroke, 2024, 19(2): 202-206.
[7]	JU Jiajun, WANG Xinxin, HANG Lihua. Research Progress on the Correlation between Neuroinflammation and Brain Iron Metabolism after Intracerebral Hemorrhage [J]. Chinese Journal of Stroke, 2024, 19(10): 1205-1214.
[8]	JIAO Junping, BAO Junqiang, SHI Huimin, GAO Chao, TIAN Shujuan. LACC1 Aggravated Ischemia Reperfusion by Phosphorylate AMP-activated Protein Kinase/Nucleotide-binding Oligomerization Domain-like Receptor Protein 3 in Cerebral Infarction [J]. Chinese Journal of Stroke, 2023, 18(9): 1006-1013.
[9]	. Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases (Second Edition) (Except) ——Chapter Three Management of Patients at Hige-risk of Cerebrovascular Diseases [J]. Chinese Journal of Stroke, 2023, 18(8): 898-909.
[10]	LIANG Jia, KANG Huibin, LI Baoqing, SUI Binbin. The Imaging Features of High Resolution Magnetic Resonance Vessel Wall Imaging in Young Patients with Intracranial Artery Stenosis [J]. Chinese Journal of Stroke, 2023, 18(11): 1255-1261.
[11]	WENG Jiaxu, ZHOU Hongyu, LI Zixiao. DNA Methylation and Hyperhomocysteinemia [J]. Chinese Journal of Stroke, 2023, 18(04): 404-409.
[12]	ZHAO Manman, CHENG Si, LI Yanran, LI Hao, WANG Yongjun. Progress of Single-cell Sequencing Analyzing Macrophage Heterogeneity in Atherosclerosis [J]. Chinese Journal of Stroke, 2023, 18(02): 180-184.
[13]	SONG Xiaowei, SANG Zhenhua, HOU Duoduo, CHEN Wenwen, ZHANG Hongliang, ZHENG Zhuozhao, ZHAO Xihai, LI Rui, WU Jian. Correlation between Blood Pressure Circadian Rhythm and Intracranial Atherosclerotic Plaque Characteristics [J]. Chinese Journal of Stroke, 2023, 18(01): 61-67.
[14]	WANG Yubo, LI Zixiao, WANG Yongjun. Progress of the Relationship between Epigenetics and Oxidative Stress after Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(11): 1171-1177.
[15]	LIU Yitong, HUANG Yanqi, LI Mingli, FENG Feng, GAO Shan, XU Weihai. Carotid Artery Geometry: A Potential Predictor for Intracranial Atherosclerosis in People at Age 60 or Less than 60 Years without Traditional Vascular Risk Factors [J]. Chinese Journal of Stroke, 2022, 17(09): 925-931.